

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

Capitol Annex -Room 149

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, November 15, 2018

1:00 P.M. to 4:00 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session**
- III. Old Business**
 - a. Approval of Meeting Minutes
 - b. Lucemyra New Product Review
- IV. New Business**
 - a. New Products to Market
 - i. Tibsovo[®] (Oncology, Oral – Hematologic)
 - ii. Braftovi[™] (Oncology, Oral – Skin)
 - iii. Mektovi[®] (Oncology, Oral – Skin)
 - iv. Doptelet[®] (Thrombopoiesis Stimulating Agents)
 - v. Mulpleta[®] (Thrombopoiesis Stimulating Agents)
 - b. New Product(s) to Market to be reviewed along with their respective classes
 - i. Ilumya[™] (Cytokine and CAM Antagonists)
- V. Clinical Criteria Review**
 - a. Austedo (Movement Disorders)
 - b. Ingrezza (Movement Disorders)
- VI. Therapeutic Classes with Recommended Changes**
 - a. Acne Agents, Topical
 - b. Anticholinergics/Antispasmodics
 - c. Antiemetics & Antivertigo Agents
 - i. Anti-Emetics: Other
 - ii. Oral Anti-Emetics: 5-HT₃ Antagonists
 - iii. Oral Anti-Emetics: Delta-9-THC Derivatives
 - iv. Oral Anti-Emetics: NK-1 Antagonists
 - d. Antifungals, Topical
 - e. Antiparasitics, Topical
 - f. Bile Salts
 - g. Cytokine and CAM Antagonists (includes new agent Ilumya[™])
 - h. Multiple Sclerosis Agents
 - i. Ophthalmics for Allergic Conjunctivitis
 - j. Ophthalmic Antibiotics
 - i. Ophthalmic Antibiotics, Non-Quinolones

- ii. Ophthalmic Antifungals
- iii. Ophthalmic Macrolides
- iv. Ophthalmic Quinolones
- k. Otic Antibiotics
- l. Steroids, Topical (Low Potency)

VII. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Acne Agents, Oral	Ophthalmic Immunomodulators
Anti-Ulcer Protectants	Ophthalmics, Antibiotic-Steroid Combinations
Antibiotics, Topical	Ophthalmics, Anti-inflammatories
Antidiarrheals	Ophthalmics, Antivirals
Antipsoriatics, Oral	Ophthalmics, Glaucoma Agents
Antipsoriatics, Topical	Ophthalmics, Mydriatic
Antivirals, Topical	Ophthalmics, Vasoconstrictors
GI Motility, Chronic	Otic Anti-Infectives and Anesthetics
H. Pylori Treatment	Otics, Anti-Inflammatory
Histamine II Receptor Blockers	Proton Pump Inhibitors
Immunomodulators, Atopic Dermatitis	Rosacea Agents, Topical
Immunosuppressives, Oral	Steroids, Topical (Medium, High, Very High)
Laxatives and Cathartics	Ulcerative Colitis Agents

VIII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **January 17, 2019**
 - ii. **March 21, 2019**
 - iii. **May 16, 2019**
 - iv. **July 18, 2019**
 - v. **September 19, 2019**
 - vi. **November 21, 2019**
- b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.